0001104659-24-095661.txt : 20240830 0001104659-24-095661.hdr.sgml : 20240830 20240830163450 ACCESSION NUMBER: 0001104659-24-095661 CONFORMED SUBMISSION TYPE: N-PX PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240830 EFFECTIVENESS DATE: 20240830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RA CAPITAL MANAGEMENT, L.P. CENTRAL INDEX KEY: 0001346824 ORGANIZATION NAME: IRS NUMBER: 830406777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-PX SEC ACT: 1934 Act SEC FILE NUMBER: 028-12884 FILM NUMBER: 241270630 BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET, 18TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-778-2500 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET, 18TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RA CAPITAL MANAGEMENT, LLC DATE OF NAME CHANGE: 20051213 N-PX 1 primary_doc.xml N-PX IM LIVE 0001346824 XXXXXXXX false false 06/30/2024 YEAR 2024 RA CAPITAL MANAGEMENT, L.P. 617-778-2500

200 Berkeley St. 18th Floor Boston MA 02116

INSTITUTIONAL MANAGER VOTING REPORT N 028-12884 N 0 RA CAPITAL MANAGEMENT, L.P. Rajeev Shah Rajeev Shah Authorized Signatory 07/23/2024 PROXY VOTING RECORD 2 proxytable.xml Wave Life Sciences Ltd. Y95308105 SG9999014716 08/01/2023 To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statement SECTION 14A SAY-ON-PAY VOTES 17202009.000000 0 FOR 17202009.000000 FOR ImmunoGen, Inc. 45253H101 US45253H1014 01/31/2024 A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to ImmunoGen's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement; and SECTION 14A SAY-ON-PAY VOTES 23716326.000000 34275.000000 FOR 23716326.000000 FOR Verona Pharma Plc 925050106 US9250501064 04/26/2024 To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 6214670.000000 103320.000000 FOR 6214670.000000 FOR Compass Pathways Plc 20451W101 US20451W1018 05/09/2024 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended 31 December 2023 SECTION 14A SAY-ON-PAY VOTES 788924.000000 16154.000000 FOR 788924.000000 FOR Geron Corporation 374163103 US3741631036 05/09/2024 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Company's Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 45879063.000000 323362.000000 FOR 45879063.000000 FOR Bicycle Therapeutics Plc 088786108 US0887861088 05/16/2024 To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement SECTION 14A SAY-ON-PAY VOTES 800000.000000 0 FOR 800000.000000 FOR MacroGenics, Inc. 556099109 US5560991094 05/21/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials. SECTION 14A SAY-ON-PAY VOTES 3353084.000000 536842.000000 FOR 3353084.000000 FOR Day One Biopharmaceuticals, Inc. 23954D109 US23954D1090 05/23/2024 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 7747198.000000 62654.000000 FOR 7747198.000000 FOR Day One Biopharmaceuticals, Inc. 23954D109 US23954D1090 05/23/2024 Selection, on a non-binding advisory basis, of whether future advisory votes on the compensation of our named executive officers should be every one, two or three years. SECTION 14A SAY-ON-PAY VOTES 7747198.000000 62654.000000 ABSTAIN 7747198.000000 AGAINST Inhibrx, Inc. 45720L107 US45720L1070 05/24/2024 To approve, by non-binding, advisory vote, certain compensation that may become payable to the Company's named executive officers in connection with the transactions contemplated by the Merger Agreement and Distribution Agreement. SECTION 14A SAY-ON-PAY VOTES 3848596.000000 14435.000000 FOR 3848596.000000 FOR 89bio, Inc. 282559103 US2825591033 05/29/2024 Approval of, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 11105732.000000 0 FOR 11105732.000000 FOR 89bio, Inc. 282559103 US2825591033 05/29/2024 Advisory vote on the frequency of future advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES 11105732.000000 0 ABSTAIN 11105732.000000 AGAINST Arvinas, Inc. 04335A105 US04335A1051 05/29/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 142607.000000 0 FOR 142607.000000 FOR Larimar Therapeutics, Inc. 517125100 US5171251003 05/29/2024 Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2023 SECTION 14A SAY-ON-PAY VOTES 6045350.000000 1.000000 FOR 6045350.000000 FOR Adicet Bio, Inc. 007002108 US0070021086 06/05/2024 To ratify, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 7006816.000000 0 FOR 7006816.000000 FOR Adicet Bio, Inc. 007002108 US0070021086 06/05/2024 To ratify, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 7006816.000000 0 ONE YEAR 7006816.000000 FOR Astria Therapeutics, Inc. 04635X102 US04635X1028 06/05/2024 The approval, by non-binding advisory vote, of our executive compensation. SECTION 14A SAY-ON-PAY VOTES 3308398.000000 0 FOR 3308398.000000 FOR Cytek Biosciences, Inc. 23285D109 US23285D1090 06/05/2024 To vote, on an advisory basis, regarding the compensation of our named executive officers for the year ended December 31, 2023. SECTION 14A SAY-ON-PAY VOTES 3870043.000000 0 FOR 3870043.000000 FOR Praxis Precision Medicines, Inc. 74006W207 US74006W2070 06/05/2024 To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2024 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. SECTION 14A SAY-ON-PAY VOTES 804527.000000 23853.000000 FOR 804527.000000 FOR Evolent Health, Inc. 30050B101 US30050B1017 06/06/2024 Proposal to approve the compensation of our named executive officers for 2023 on an advisory basis. SECTION 14A SAY-ON-PAY VOTES 5724439.000000 11693.000000 FOR 5724439.000000 FOR Evolent Health, Inc. 30050B101 US30050B1017 06/06/2024 Proposal to approve the selection of the frequency of future advisory votes on executive compensation on an advisory basis. SECTION 14A SAY-ON-PAY VOTES 5724439.000000 11693.000000 ONE YEAR 5724439.000000 FOR RXSight, Inc US78349D1072 06/06/2024 Advisory Vote to Ratify Named Executive Officers' Compensation SECTION 14A SAY-ON-PAY VOTES 1177796.000000 0.000000 FOR 1177796.000000 FOR RXSight, Inc US78349D1072 06/06/2024 Advisory Vote on Say on Pay Frequency SECTION 14A SAY-ON-PAY VOTES 1177796.000000 0.000000 FOR 1177796.000000 FOR RxSight, Inc. 78349D107 US78349D1072 06/06/2024 To approve, on an advisory basis, the compensation of the named executive officers identified in the 2023 Summary Compensation Table in the "Executive Compensation" section of the proxy statement (the "Say-on-Pay Vote"). SECTION 14A SAY-ON-PAY VOTES 2449171.000000 0 FOR 2449171.000000 FOR RxSight, Inc. 78349D107 US78349D1072 06/06/2024 To approve, on an advisory (non-binding) basis, the frequency of future Say-on-Pay Votes. SECTION 14A SAY-ON-PAY VOTES 2449171.000000 0 ABSTAIN 2449171.000000 AGAINST Vaxcyte, Inc. 92243G108 US92243G1085 06/06/2024 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 6212874.000000 0 FOR 6212874.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/07/2024 To approve, by non-binding advisory vote, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 1000000.000000 0 FOR 1000000.000000 FOR Solid Biosciences Inc. US83422E2046 06/11/2024 Advisory Vote to Ratify Named Executive Officers' Compensation SECTION 14A SAY-ON-PAY VOTES 3618551.000000 0.000000 FOR 3618551.000000 FOR Solid Biosciences Inc. US83422E2046 06/11/2024 Advisory Vote on Say on Pay Frequency SECTION 14A SAY-ON-PAY VOTES 3618551.000000 0.000000 FOR 3618551.000000 FOR Solid Biosciences Inc. 83422E204 US83422E2046 06/11/2024 The approval of an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 711895.000000 0 FOR 711895.000000 FOR Solid Biosciences Inc. 83422E204 US83422E2046 06/11/2024 The holding of an advisory vote on the frequency of future executive compensation advisory votes. SECTION 14A SAY-ON-PAY VOTES 711895.000000 0 ONE YEAR 711895.000000 FOR Vaxart, Inc. 92243A200 US92243A2006 06/11/2024 To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 12559025.000000 0 FOR 12559025.000000 FOR Avidity Biosciences, Inc. US05370A1088 06/13/2024 Advisory Vote to Ratify Named Executive Officers' Compensation SECTION 14A SAY-ON-PAY VOTES 1212122.000000 0.000000 FOR 1212122.000000 FOR Avidity Biosciences, Inc. 05370A108 US05370A1088 06/13/2024 To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in the related proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and SECTION 14A SAY-ON-PAY VOTES 2252623.000000 58176.000000 FOR 2252623.000000 FOR Pliant Therapeutics, Inc. 729139105 US7291391057 06/13/2024 To approve, by non-binding advisory vote, the resolution approving named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 995286.000000 0 FOR 995286.000000 FOR Biogen Inc. US09062X1037 06/20/2024 Advisory Vote to Ratify Named Executive Officers' Compensation SECTION 14A SAY-ON-PAY VOTES 150000.000000 0.000000 FOR 150000.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/20/2024 Say on Pay - To hold an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 732620.000000 36697.000000 FOR 732620.000000 FOR C4 Therapeutics, Inc. US12529R1077 06/20/2024 Advisory Vote to Ratify Named Executive Officers' Compensation SECTION 14A SAY-ON-PAY VOTES 1116018.000000 0.000000 FOR 1116018.000000 FOR C4 Therapeutics, Inc. 12529R107 US12529R1077 06/20/2024 To cast a non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 3651800.000000 0 FOR 3651800.000000 FOR Chimerix, Inc. 16934W106 US16934W1062 06/20/2024 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 8800000.000000 0 FOR 8800000.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/20/2024 To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES 1457076.000000 0 FOR 1457076.000000 FOR Madrigal Pharmaceuticals, Inc. 558868105 US5588681057 06/25/2024 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 420953.000000 0 FOR 420953.000000 FOR